Update on systemic therapy for clear cell renal cell carcinoma

被引：1
|
作者：
Muehlmann, Josef [1 ]
机构：
[1] Hosp Barmherzige Bruder Bros Mercy, Dept Internal Med, Kajetanerpl 1, A-5020 Salzburg, Austria
来源：
MEMO-MAGAZINE OF EUROPEAN MEDICAL ONCOLOGY | 2023年 / 16卷 / 01期
关键词：
Adjuvant therapy; Belzutifan; First-line therapy; Second-line therapy; Pembrolizumab; PHASE-III; COMBINATION; RISK;
D O I：
10.1007/s12254-022-00867-w
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
The treatment landscape of advanced and metastatic renal cell carcinoma (RCC) has changed fundamentally over the last two decades with the introduction of tyrosine kinase inhibitors (TKIs) in 2005 and immune checkpoint inhibitors (ICIs) about 10 years later, both demonstrating significantly improved overall survival (OS) rates across all RCC risk categories. Currently, combination therapies represent the standard-of-care in the first-line setting of clear cell RCC in almost all cases. In this short review article, the most recent therapeutic advances in early and advanced stage of clear cell RCC are summarized.
引用
收藏
页码：38 / 41
页数：4
相关论文
共 50 条
  • [1] Update on systemic therapy for clear cell renal cell carcinoma
    Josef Mühlmann
    [J]. memo - Magazine of European Medical Oncology, 2023, 16 : 38 - 41
  • [2] Updates in the Systemic Therapy Options for Clear Cell and Non-Clear Cell Renal Cell Carcinoma
    Spiess, Philippe E.
    Johnstone, Peter A. S.
    Jonasch, Eric
    [J]. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2023, 21 (5.5):
  • [3] Update on Radiogenomics of Clear Cell Renal Cell Carcinoma
    Alessandrino, Francesco
    Krajewski, Katherine M.
    Shinagare, Atul B.
    [J]. EUROPEAN UROLOGY FOCUS, 2016, 2 (06): : 572 - 573
  • [4] Modern Systemic Therapy for Metastatic Renal Cell Carcinoma of the Clear Cell Type
    Parikh, Mamta
    Lara, Primo N., Jr.
    [J]. ANNUAL REVIEW OF MEDICINE, VOL 69, 2018, 69 : 209 - 221
  • [5] Pathology and systemic therapy of non-clear cell renal cell carcinoma: an overview
    Bergmann, Lothar
    Weber, Sarah
    Hartmann, Arndt
    Ahrens, Marit
    [J]. EXPERT REVIEW OF ANTICANCER THERAPY, 2021, 21 (11) : 1273 - 1286
  • [6] Update on targeted therapies for clear cell renal cell carcinoma
    Singer, Eric A.
    Gupta, Gopal N.
    Srinivasan, Ramaprasad
    [J]. CURRENT OPINION IN ONCOLOGY, 2011, 23 (03) : 283 - 289
  • [7] The genomic landscape of metastatic clear cell renal cell carcinoma after systemic therapy
    van der Mijn, Johannes C.
    Eng, Kenneth W.
    Chandra, Pooja
    Fernandez, Evan
    Ramazanoglu, Sinan
    Sigaras, Alexandros
    Oromendia, Clara
    Gudas, Lorraine J.
    Tagawa, Scott T.
    Nanus, David M.
    Faltas, Bishoy F.
    Beltran, Himisha
    Sternberg, Cora N.
    Elemento, Olivier
    Sboner, Andrea
    Mosquera, Juan Miguel
    Molina, Ana M.
    [J]. MOLECULAR ONCOLOGY, 2022, 16 (12) : 2384 - 2395
  • [8] Efficacy of systemic therapy for metastatic non clear renal cell carcinoma
    Mizuno, R.
    Takamatsu, K.
    Hayakawa, N.
    Tanaka, N.
    Kosaka, T.
    Oya, M.
    [J]. INTERNATIONAL JOURNAL OF UROLOGY, 2019, 26 : 192 - 192
  • [9] Update on the treatment of metastatic clear cell and non-clear cell renal cell carcinoma
    Xu K.Y.
    Wu S.
    [J]. Biomarker Research, 3 (1)
  • [10] Trends in Initial Systemic Therapy for Elderly Patients with Metastatic Clear Cell Renal Cell Carcinoma
    Osterman, Chelsea K.
    Deal, Allison M.
    Milowsky, Matthew, I
    Bjurlin, Marc A.
    Rose, Tracy L.
    [J]. KIDNEY CANCER, 2020, 4 (03) : 131 - 137
12345